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Abstract
Background: Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer and the most difficult to
predict. When there are no distant metastases, the optimal therapy depends mainly on whether there are malignant
lymph nodes in the mediastinum. Given the vigorous debate among specialists about which tests should be used, our
goal was to determine the optimal sequence of tests for each patient.
Methods: We have built an influence diagram (ID) that represents the possible tests, their costs, and their outcomes.
This model is equivalent to a decision tree containing millions of branches. In the first evaluation, we only took into
account the clinical outcomes (effectiveness). In the second, we used a willingness-to-pay of e 30,000 per quality
adjusted life year (QALY) to convert economic costs into effectiveness. We assigned a second-order probability
distribution to each parameter in order to conduct several types of sensitivity analysis.
Results: Two strategies were obtained using two different criteria. When considering only effectiveness, a positive
computed tomography (CT) scan must be followed by a transbronchial needle aspiration (TBNA), an endobronchial
ultrasound (EBUS), and an endoscopic ultrasound (EUS). When the CT scan is negative, a positron emission
tomography (PET), EBUS, and EUS are performed. If the TBNA or the PET is positive, then a mediastinoscopy is
performed only if the EBUS and EUS are negative. If the TBNA or the PET is negative, then a mediastinoscopy is
performed only if the EBUS and the EUS give contradictory results. When taking into account economic costs, a
positive CT scan is followed by a TBNA; an EBUS is done only when the CT scan or the TBNA is negative.
This recommendation of performing a TBNA in certain cases should be discussed by the pneumology community
because TBNA is a cheap technique that could avoid an EBUS, an expensive test, for many patients.
Conclusions: We have determined the optimal sequence of tests for the mediastinal staging of NSCLC by
considering sensitivity, specificity, and the economic cost of each test. The main novelty of our study is the
recommendation of performing TBNA whenever the CT scan is positive. Our model is publicly available so that
different experts can populate it with their own parameters and re-examine its conclusions. It is therefore proposed as
an evidence-based instrument for reaching a consensus.
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Background
Lung cancer is a very common tumor in the developed
world and the leading cause of cancer death. Lung can-
cer can be classified into two major types: small-cell lung
cancer and NSCLC. The former, which accounts for 20%
of cases [1], is usually inoperable and treatable only with
chemotherapy or chemoradiotherapy. In contrast, when
it is limited to the lung, to certain adjacent structures,
and to lymph nodes proximal to the lung, NSCLC can be
treated with surgical resection. However, more than 80%
ofNSCLC patients cannot be treated with surgery because
the disease is out of control due to a metastasis [2]. A dis-
appointing fact is that a high percentage of patients that
may benefit from surgery die of lung cancer. A correct
assessment at an early stage of the disease—the staging
phase—would help to determine which patients may ben-
efit from surgery and, in turn, to avoid dangerous, painful,
and unnecessary surgery when metastasis has already
occurred.
When there are no distant metastases, mediastinal
staging, i.e., determining whether malignant mediasti-
nal lymph nodes are present or absent, is the most
important prognostic factor in patients with NSCLC
and, consequently, determines the therapeutic strategy.
Various techniques are available to study the medi-
astinum, such as non-invasive imaging techniques (CT
scan and PET) and minimally invasive endoscopic tech-
niques (TBNA, EBUS, EUS), involving varying degrees
of sensitivity and specificity; more invasive surgical tech-
niques include mediastinoscopy. The main treatment
options for lung cancer include surgery, chemotherapy,
radiation therapy, chemoradiotherapy, palliative and sup-
portive care, and no treatment. The applicability of
each treatment depends on the stage of the tumor.
Due to the variety of available tests and treatments for
NSCLC, each one with its pros and cons and differ-
ent economic costs, there is a vigorous debate among
specialists about which tests and treatments should
be used to strike a balance between effectiveness and
costs [3, 4].
In an attempt to clarify this controversy using an
evidence-based approach [5–7], we have built an ID
for this problem from the perspective of the Spanish
public health system. The ID was evaluated twice,
first without considering economic costs, and then by
converting costs into effectiveness using a willingness-
to-pay of e30,000 per QALY, the shadow threshold
estimated for that health system [8, 9]. We performed
several types of sensitivity analysis to study the effect
of the uncertainty in the numerical parameters of the
model.
This paper has been written following the Con-




This section describes IDs, the explanation capabilities
available in the software tool used to build the model,
and the basic principles of cost-effectiveness analysis in
medicine.
Influence diagrams
Decision trees [11] are a traditional framework for
modeling decision problems in medicine. Since decision
trees explicitly represent all the possible decision scenar-
ios, the size of the model grows exponentially with the
number of variables. That combinatorial explosion makes
the use of decision trees prohibitive for medium or large
problems.
IDs [12, 13] arose as an alternative to decision trees.
Their compactness, based on a causal graph, eases com-
munication with experts, simplifies the solution and
debugging, and thus makes IDs appropriate for much
larger decision problems.
We start by considering an example of a medical
ID. A physician has to decide whether to treat or
not a patient, who may suffer from a disease (X).
Before deciding how to treat the patient (D), the physi-
cian can perform a test (decision T), whose result
(Y ) will help determine whether the patient suffers
from the disease. The overall effectiveness results from
substracting the morbidity of the test (U1) from the
quality of life that results from treating the patient
(U2).
Formally, an ID consists of an acyclic directed graph
having three disjoint sets of nodes: decision nodes VD
(graphically represented by squares or rectangles), chance
nodes VC (circles or ovals), and utility nodes VU (dia-
monds or hexagons). Decision nodes represent the actions
under the direct control of the decision maker. Chance
nodes represent uncertain events. In medical IDs, util-
ity nodes represent medical outcomes and costs (quality
of life, morbidity, mortality, economic cost...). Here, two
types of utility nodes are distinguished: ordinary, having
parents that are chance and decision nodes, and super-
value (SVN), having parents that are other utility nodes
[14]. Given that each node represents a variable, we will
use the concepts of node and variable interchangeably.
We assume that all the chance and decision variables are
discrete.
IDs contain three types of arcs, depending on the type
of node they go into. Arcs into chance nodes represent
probabilistic dependencies. Arcs into decision nodes rep-
resent availability of information or precedence relations
between decisions. Arcs into ordinary utility nodes indi-
cate the domain of the associated utility function; arcs into
a SVN U indicate that the associated utility function is a
combination of the utility functions of the parents of U.
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For example, in Fig. 1 X and Y are chance nodes, T and
D are decision nodes, U1 and U2 are utility nodes, and the
child of U1 and U2 is a SVN of type sum. Node X has a
causal and probabilistic relationship with node Y. Variable
X is not observable, is unknown when making decision D
and there is thus no arc from node X to node D. How-
ever, variable Y is observable, its values are known when
making decision D, and it can therefore be observed by
the decision maker at that moment. This explains the arc
pointing Y to node D.
We assume a path connects all the decision nodes, indi-
cating the order in which decisions are made. Let n be the
number of decisions in the ID. The total order of decisions
{D0,D1, . . . ,Dn−1} partitions the set of chance variables
into the collection of sets {C0,C1, . . . ,Cn}, where Ci, 0 ≤
i < n, is the subset of chance variables known for Di but
unknown for any previous decision, and Cn is the set of
unknown chance variables. Furthermore, the no-forgetting
hypothesis [15] is assumed, which states that the decision
maker recalls all the previous decisions and observations.
For example, in Fig. 1 decision T precedes decision D,
i.e., D0 = T and D1 = D. This order partitions the set of
chance variables in the following way: C0 = ∅,C1 = {Y }
and C2 = {X}. This partition has a simple interpretation:
no chance variable is observed before deciding on T, vari-
able Y is observed after deciding on T but before deciding
on D, and variable T is unknown or observed after decid-
ing on D. Thus, when deciding on D, the decision maker
knows the values of T and Y.
Fig. 1 Example of medical influence diagram. A patient may suffer
from a disease (X). Before deciding how to treat the patient (D), the
physician can decide to perform a test (T ). This test will produce the
test result (Y), which would help to determine whether the patient
suffers from the disease. The doctor has to select a strategy taking
into consideration the morbidities associated to the test (U1) and the
health state of the patient after treating him (U2)
The quantitative information that defines an ID is
given by (1) assigning to each chance node a conditional
probability, (2) assigning to each ordinary utility node a
real-valued function, and (3) assigning to each SVN a
utility-combination function. Conditional probabilities
and utility functions of ordinary utility nodes are repre-
sented as tables. In the example, the quantitative infor-
mation consists of the conditional probabilities P(x) and
P(x|y) and the utility functions ψ1(x, d) and ψ2(t).
The optimal policy for a decision D is a function that
maps each configuration of the variables known in D onto
the option of D that maximizes the expected utility. The
purpose of evaluating an ID is to compute an optimal
strategy composed of a set of optimal policies, one for each
decision in the ID.
It is well known that inference in probabilistic graphical
models, such as Bayesian networks and IDs, is an NP-hard
problem [16, 17]. Although the set of decisions is totally
ordered in IDs, the search space of an ID solution algo-
rithm grows exponentially with the number of variables.
However, there are algorithms and software packages that
can evaluate BNs and IDs for many real-world problems
in less than a second.
In this paper, the ID was built using Elvira and Open-
Markov, two software tools for probabilistic graphical
models [18, 19]. Debugging a probabilistic expert system
based on an ID is very difficult because the output of the
evaluation of a medium or large problemmay be the result
of thousands of mathematical operations such as sums,
products, divisions, and maximizations. Explaining the
reasoning is a key factor in the acceptance of expert sys-
tems in real-world domains like medicine. One example
consists of explaining why the system recommends one
action instead of another. Lacave et al. [20, 21] described
how the explanation capabilities of Elvira were useful for
building probabilistic medical models and how such capa-
bilities can help make the probabilistic reasoning more
understandable to human users. However, it is a very dif-
ficult task that has not yet been completely solved in the
field of IDs [20].
Cost-effectiveness analysis inmedicine
If economic costs are included in a medical decision prob-
lem, the result is a problem with two criteria to optimize:
effectiveness, measured in clinical units, usually QALYs,
which we want to maximize, and cost, measured in mon-
etary units, which we want to minimize1. In medicine,
this problem is typically solved with cost-effectiveness
analysis [22].
The goal of cost-effectiveness analysis is to maximize
the net health benefit (NHB) [23], which is defined as
follows:
NHB = E − C/λ , (1)
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where E is effectiveness, C is cost2, and λ is used to con-
vert effectiveness into cost or vice versa. Parameter λ is
sometimes called willingness to pay and represents the
maximum amount of money an individual is willing to
sacrifice to gain a unit of effectiveness (health benefit).
The value of λ is always positive but depends on each
decision maker.
Construction of the model
This section describes the construction of MEDIASTINET,
an ID for determining the optimal sequence of tests for the
mediastinal staging of NSCLC. The model was developed
with the help of a pneumologist during several oral inter-
views; the pneumologist is the third author of this paper.
The perspective adopted in the model was that from the
Spanish public health system. The primary decisionmaker
is the Spanish Ministry of Health. Our model applies to
patients that have lung cancer, presumably operable, with
no distant metastases.
The model assumes that a CT scan is always performed.
Silvestri et al. [24] state that a “CT scan is clearly an imper-
fect means of staging of the mediastinum, but it remains
the best overall anatomic technique for studying the tho-
rax”. Additionally, the authors highlight the importance
of CT scan, a non-invasive test, for guiding the choice of
nodes for the most invasive techniques.
Structure of the graph
The graph structure of the ID (see Fig. 2) was built man-
ually following the expert’s knowledge of the variables
involved in the problem and the causal relations between
them.
Chance variables The TNM classification uses three fac-
tors (T, N, and M) to describe the extent of a cancer.
The N factor indicates whether regional lymph nodes are
affected. Given that the objective is the mediastinal stag-
ing of NSCLC, the value of N [1] has been represented
by the chance variable N2_N3. Even though N takes on
four possible values, from N0 to N3, it has been mod-
eled here as a binary variable because cancers are operable
for groups N0 and N1, and inoperable for most of N2
and all of N3. The laboratory tests that can be performed
are represented by binary variables CT_scan, TBNA, PET,
EBUS, EUS, andMED (mediastinoscopy). Binary variable
MED_Sv represents whether the patient survives medi-
astinoscopy.
Nodes representing test results (CT_scan, TBNA, PET,
EBUS, EUS, EUS, and MED) have a causal and proba-
bilistic relationship with node N2_N3. This justifies the
arcs pointing from N2_N3. Moreover, we have drawn arcs
from CT_scan to the other test result variables because
the CT_scan result can influence their sensitivity and
specificity.
Decision variables Each decision on whether to perform
a laboratory test has been represented by a variable with
the prefix Dec_ on its name. A node Dec_CT_scan was
not included because a CT scan is always done. The deci-
sion maker can perform the EBUS and EUS separately,
or both at the same time; this is represented by node
Dec_EBUS_EUS. These decisions forced the addition of a
new state no_result to the variables TBNA, PET, EBUS,
EUS, and MED, to reflect the fact that when a test is not
performed, its result is not available. Variable Treatment
represents the set of possible treatments; its states are
thoracotomy, chemoradiotherapy, and no_treatment.
We included a node Treatment because the effective-
ness of the tests is due to the guide they offer on which
treatment to apply.
Utility nodes Utility nodes in the ID of Fig. 2 can be
grouped into three sets, each surrounded by a dashed
rectangle.
The first group represents effectiveness, measured in
QALYs. The node Total_QALE accumulates the overall
quality adjusted life expectancy (QALE) of patients [25].
This node sums the morbidities due to medical tests,
and the utility function of Net_QALE. This last node rep-
resents the QALE of patients considering that they can
die due to the treatment or to the mediastinoscopy, and
is the product of three nodes: Surv_QALE represents
the QALE of the survivors of the tests and treatments;
MED_Survival indicates whether the patient survives the
mediastinoscopy; and Immediate_Survival represents the
immediate survival rate after the treatment.
The second group of utility nodes represents cost.
Total_Economic_Cost is the total cost. Its parents in the
graph represent the costs of tests and treatments.
Finally, the third group relates cost and effective-
ness: λ−1 represents (the inverse of ) the willingness
to pay, Weighted_Econ_Cost represents λ−1 · C, and
Net_Health_Benefit the NHB (Eq. 1). The reason for using
λ−1 instead of λ is to be able to obtain the optimal policy
regardless of cost, as shown below.
Table 1 presents a list of all the variables, along with the
type of variable (chance, decision or utility), the domain
(discrete or continuous), and the set of possible values
(domain).
Elicitation of probabilities and utilities
There are two types of uncertainty in a model. First-order
uncertainty reflects that the outcomes of some variables
are not under the control of the decision maker. For
example, even if a doctor knows that the prevalence of a
disease is 0.05, s/he cannot know with certainty whether
a person randomly chosen has the disease. Second-order
uncertainty reflects that the parameters of the probabil-
ity distribution are not known with certainty [26, 27]. For
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Fig. 2 Influence diagram MEDIASTINET. Chance nodes (ovals), except N2_N3 andMED_Sv, correspond to the laboratory tests that can be performed.
Decision nodes (rectangles) correspond to the decision on the treatment and on whether to perform each laboratory test. Utility nodes (hexagons
or diamonds) have been grouped into three sets, each one surrounded by an orange rectangle background. The first group represents
effectiveness, measured in QALYs. The second group of utility nodes represents cost, measured in e. The third group relates cost and effectiveness.
Node λ−1 represents (the inverse of) the willingness to pay
example, a doctor may not know with certainty the value
of the prevalence of a disease, but s/he could assume that
its distribution follows a Beta with parameters α = 5 and
β = 95. In this example, the prevalence of the disease is a
parameter of the model, while α and β are the parameters
of the associated second-order distribution.
The next step in the construction of the model was to
complete the quantitative part of the ID, consisting of a set
of probability and utility potentials. There were 46 inde-
pendent parameters. Each parameter of the model, except
costs, had an associated second-order probability:
• Beta distributions were assigned to the non-extreme
probabilities of the prevalence of the disease, the
sensitivities and the specificities of tests, and the
survival rates, as the data that inform each probability
parameter of the model are binomial (m cases of
interest are observed from a set of n observations)
[27], and the Beta distribution is the conjugate to
binomial data [28].
• Uniform distributions were assigned to the
morbidities of the tests. As the literature provided us
with the percentage of patients suffering the
morbidities and the medical expert said that the
effects only last for a month after the test, we
subjectively assumed that the quality of life of
patients due to the morbidities follow a uniform
distribution in the interval [0, 1]. We have
accordingly selected in this case the type of
distribution with maximum entropy. This estimation
of the quality of life is imprecise, but the subsequent
sensitivity analysis demonstrated that the calculated
strategy was not sensitive to the uncertainty in the
morbidity parameters.
• Although λ was known with certainty, we attached it
a second-order distribution in order to analyze its
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Table 1 Variables of the influence diagram, along with their type,
the domain type and the values they can take
Name Type Domain type Domain
N2_N3 Chance Discrete positive; negative
CT_scan Chance Discrete positive; negative
TBNA Chance Discrete positive; negative;
no_result
PET Chance Discrete positive; negative;
no_result
EBUS Chance Discrete positive; negative;
no_result
EUS Chance Discrete positive; negative;
no_result
MED Chance Discrete positive; negative;
no_result
MED_Sv Chance Discrete yes; no
Dec_TBNA Decision Discrete yes; no
Dec_PET Decision Discrete yes; no
Dec_EBUS_EUS Decision Discrete ebus+eus;ebus;eus;
no_test
Dec_MED Decision Discrete yes; no
Treatment Decision Discrete thoracotomy;
chemoradiotherapy;
no_treatment
EC_CT_scan Utility Continuous R+
EC_TBNA Utility Continuous R+
EC_PET Utility Continuous R+
EC_EBUS Utility Continuous R+
EC_EUS Utility Continuous R+
EC_MED Utility Continuous R+
EC_Treatment Utility Continuous R+
TBNA_Morb Utility Continuous R−
EBUS_Morb Utility Continuous R−
EUS_Morb Utility Continuous R−
MED_Morb Utility Continuous R−
Immediate_Survival Utility Continuous [0, 1]
MED_Survival Utility Discrete 0; 1
Surv_QALE Utility Continuous R+
λ−1 Utility Continuous R+
variations in the sensitivity analysis phase. A Gamma
distribution was assigned to λ, as it is constrained in
the interval [0,+∞) [27] and it can be interpreted as
a cost. Briggs et al. [27] suggest the use of gamma for
costs because the count data of costs is often usually
represented by the Poisson distribution, and the
Gamma is the conjugate to the Poisson.
The parameters of the second-order distributionswere
estimated from the medical literature. Different methods
were used to fit these distributions. In the case of Beta
distributions, four differentmethods were used depending
on the values provided by the literature:
1. If the source indicated that m cases of interest were
observed from a set of n observations, then we
elicited a Beta with shape parameters α = m and
β = n.
2. If the source only provided mean μ, we set a
coefficient of variation k, and we assigned the
standard deviation as σ = k · μ. Then by using the
method of moments [27] we calculated the shape
parameters α and β : z = (μ · (1 − μ) · σ 2) − 1,
α = z · μ, β = z − α. We have taken the value
k = 1/5, following Bond et al. [29, 30] in a study
commissioned by the National Institute for Health
and Care Excellence (NICE). If μ was so close to 1
that it was inconsistent to have a Beta with such
parameters μ and σ , then we took the value
k = 10−m · 1/5 for setting σ , where m is the
minimum natural number guaranteeing consistency.
3. If the source provided mean μ and the 95%
confidence interval (CI) [l,u] of the parameter, we
found a Beta distribution with mean μ so that the
interval [l,u] accumulated a 95% of the probability
mass. Given mean μ and considering α an
independent parameter, we have β = α · (1 − μ)/μ.
Then we used a bisection method to find the value of
α that fulfills F(u) − F(l) = 0.95, being F the
cumulative distributive function of Beta.
4. If the source provided mean μ and two values l and
u, the latter being the maximum and the minimum
values respectively, but the authors did not indicate
that l and u referred to the 95% CI, then by
assuming that the interval [l,u] accumulates 99.9 %
of the probability mass we elicited the distribution
analogously to point 3. This value is arbitrary but does
not significantly affect the sensitivity analysis results.
In the case of the Gamma distribution of λ, we fol-
lowed an approach similar to case 3 above: a mean μ was
obtained from the source, and we assigned the standard
deviation σ = k · μ, being k the coefficient of variation
explained above.
Tables 2, 3, 4, 5 and 6 present all the independent
parameters. Subindices attached to the CIs indicate the
type of distribution and the type of elicitation used:
numbers 1 to 4 correspond to a point above for the
Beta distribution, and number 5 corresponds to uniform
distributions.
All the explanation capabilities for IDs that Elvira and
OpenMarkov offer were useful in this quantitative phase
of model construction [20, 21]. The display of several evi-
dence cases made it possible to introduce evidence from
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Table 2 Sensitivities and specificities of the tests when CT scan is
positive
Sensitivity Specificity
Mean CI Mean CI Source
TBNA 78 [40.9, 98.5]2 99.5 [94.3, 100]2 [24]
PET 91 [86.7, 94.5]4 78 [71.9, 83.6]4 [56]
EBUS 92.5 [25.5, 100]2 99.5 [94.3, 100]2 [57]
EUS 90 [32.5, 100]2 99.5 [94.3, 100]2 [58]
MED 83 [39.9, 99.9]2 99.9 [100, 100]2 [24]
Mean and 95 % CI values are given in percentages. Subindices denote the
elicitation method (see Section “Elicitation of probabilities and utilities”)
medical tests and to study its effect on the posterior prob-
ability of the variable N2_N3. For example, Fig. 3 shows
two evidence cases in OpenMarkov: the first one (col-
ored in red) contains no evidence and the probability
of each variable is the prior probability; the second case
(colored in blue) contains two contradictory findings, as
the CT scan is positive and the TBNA is negative. The
bars in node N2_N3 show that the probability of posi-
tive N2_N3 is lower in the second case than the prior
probability. When the pneumologist asked us why the
model recommended not performing a certain test, we
could impose a policy on that test and analyze the out-
comes. This phase of debugging was essential for checking
the external consistency of the model, as recommended
in [31].
Results
Computation and representation of optimal strategies
The first step after building the model was to evaluate the
reference case of MEDIASTINET, i.e., the version in which
every parameter of themodel is set to themean of its asso-
ciated second-order probability distribution. To have an
idea of how big is the search space of evaluating MEDI-
ASTINET, we must note that the size of the set of possible
strategies for the set of test decisions is 2.44 × 1011.
Table 3 Sensitivities and specificities of the tests when CT scan is
negative
Sensitivity Specificity
Mean CI Mean CI Source
TBNA 4 [2.6, 5.7]2 97.1 [89.7, 99.9]1 [59]
PET 75 [66.2, 82.9]4 93 [92.4, 93.6]4 [56]
EBUS 69.2 [39.3, 91.9]2 99.5 [94.3, 100]2 [60, 61]
EUS 58 [34.7, 79.5]2 99.5 [94.3, 100]2 [58]
MED 47 [28.9, 65.5]2 99.9 [100, 100]2 [24]
Mean and 95 % CI values are given in percentages. In the case of the sensitivity and
the specificity of the EBUS, we considered that the mean value of the distribution
was the average of the values given by the two references
Table 4 Morbidities and costs of tests
Morbidity Cost
Mean CI Source Mean CI Source
CT_scan 199 — [62, 63]
TBNA 0.000108 [0.000005, 0.000211]6 [64] 80 — [65]
PET 1290 — [62, 63]
EBUS 0.000021 [0.000001, 0.000041]6 [66] 620 — [67, 68]
EUS 0.000125 [0.000006, 0.000244]6 [66] 620 — [67, 68]
MED 0.000833 [0.000042, 0.001625]6 [69] 3000 — [65]
Moribidities are given in QALYs and costs are given in e
Two strategies were computed using two different
criteria: maximizing effectiveness (disregarding costs) and
maximizing the NHB. The former was carried out by
setting λ−1 to 0, which according to Eq. 1 means that
costs are ignored. In the latter, λ−1 = 1/(30, 000
e/QALY) because the shadow willingness-to-pay thresh-
old for the Spanish public health system was estimated
to be 30,000 e/QALY [8, 9]. This threshold is consistent
with the ones proposed by theWorld Health Organization
for determining whether an intervention is considered
cost-effective [32, 33].
Computing these two strategies with different cri-
teria helps to fulfill the recommendation of check-
ing the internal consistency of the model [31] by
assigning extreme values for some parameters. In
our case, we should expect that the strategy pro-
vided by the model when setting λ−1 to 0 would
tend to select expensive tests that are discarded when
λ = 30, 000 e/QALY.
These two versions of the ID were evaluated using the
variable elimination algorithm [34]. The decision table
for each decision grows exponentially with the number
of variables known when making the decision. These
tables are not an adequate output for a human expert,
not only because of their size—for example, the pol-
icy table for decision Treatment has 15,552 columns—
but also because most of the columns correspond to
impossible scenarios. For this reason, an algorithm [35]
was developed to transform the set of decision tables
into a single strategy tree, as shown in Figs. 4 and 5.
Table 5 QALE depending on the treatment, given in QALYs
pos. N2N3 neg. N2N3
Mean CI Source Mean CI Source
Thoracotomy 1.17 [0.78, 1.56]5 [70] 5.75 [5.36, 6.14]5 [71]
Chemoradiotherapy 1.25 [0.86, 1.64]5 [70] 2.64 [2.25, 3.03]5 [72]
No treatment 0.42 [0.03, 0.81]5 [73] 2.08 [1.69, 2.47]5 [73]
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Table 6 Mean and CI of the remaining parameters of the model
Mean CI Source
Prevalence of N2_N3 30 [19, 42.4]2 [24]
Sensitivity of CT_scan 55 [33.2, 75.8]2 [24]
Specificity of CT_scan 81 [40.5, 99.5]2 [24]
MED survival rate 99.9 [99.9, 99.9]2 [69]
Thoracotomy immediate
survival rate, pos. N2_N3
96 [93.5, 97.9]3 [71]
Thoracotomy immediate
survival rate, neg. N2_N3
97.8 [92.7, 99.9]2 [74]
Chemoradiotherapy
immediate survival rate
98 [92.7, 99.9]2 [71]




λ 30000 — [8, 9]
All parameters, except costs and λ, are given in percentages. Costs are given in e.
The value of λ is given in e/QALY
This algorithm builds an auxiliary Bayesian network from
the ID by replacing each decision node with a chance
node whose probability potential is taken from the cor-
responding decision table obtained in the evaluation.
The strategy tree is then built incrementally by pruning
the scenarios incompatible with the policies for previous
decisions.
Strategy disregarding costs
When costs are disregarded and the CT scan is positive,
a TBNA, EBUS, and EUS are performed. If the TBNA is
positive and the EBUS and EUS are negative, then doing
a mediastinoscopy is recommended; otherwise, a medi-
astinoscopy is not necessary. If the TBNA is negative, then
a mediastinoscopy is performed only if the EBUS and the
EUS give contradictory results.
When the CT scan is negative, a PET, EBUS, and
EUS are performed. If the PET is positive, then doing a
mediastinoscopy is recommended only when the EBUS
and EUS are negative. If PET is negative, then a medi-
astinoscopy is performed only when the EBUS and EUS
give contradictory results.
With regards to the treatment, when the TBNA or the
PET is positive and EBUS and EUS are the last tests to
perform, then the optimal therapy is chemoradiotherapy if
the EBUS or EUS is positive, and thoracotomy otherwise.
When the TBNA or the PET is negative or when themedi-
astinoscopy is performed, in all cases the optimal therapy
is chemoradiotherapy when the last test is positive and
thoracotomy when it is negative.
Fig. 3 Debugging MEDIASTINET with OpenMarkov. Two evidence cases are displayed in OpenMarkov: the prior case (colored in red), in which no
evidence has been introduced, and an evidence case in which the CT scan is positive and the TBNA is negative (colored in blue). Evidential nodes
are colored in gray. Bars in each node indicate the posterior probability (chance or decision nodes) or the expected utility (utility nodes) of the
corresponding evidence case
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Fig. 4 Optimal strategy for MEDIASTINET disregarding costs (λ−1= 0). When the CT scan is positive, a TBNA, EBUS, and EUS are performed. When the
CT scan is negative, a PET, EBUS, and EUS are performed. If the TBNA or the PET is positive, then a mediastinoscopy is performed only if the EBUS and
EUS are negative. If the TBNA or the PET is negative, then a mediastinoscopy is performed only if the EBUS and the EUS give contradictory results
Strategy with costs
When λ = 30, 000 e/QALY, a positive CT scan must be
followed by a TBNA. An EBUS is done only when the CT
scan or the TBNA are negative. PET is never carried out;
put another way, PET is never cost-effective for this value
of willingness to pay. The optimal therapy is chemora-
diotherapy when the last test is positive and thoracotomy
when it is negative.
Sensitivity analyses
Given the uncertainty of the numerical parameters, three
types of sensitivity analyses were performed.
The first type of analysis is based on the expected value
of perfect information (EVPI); it computes the gain in
expected utility that we would obtain if the value of the
parameter to study were known with certainty [36]. For
the proposed model, the EVPI was lower than 10−2 for all
Fig. 5 Optimal strategy for MEDIASTINET with costs (λ−1 = 1/(30,000 e/QALY)). A positive CT scan must be followed by a TBNA. An EBUS is done
only when the CT scan or the TBNA is negative
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parameters except for the specificity of the EBUSwhen the
CT scan is negative.
The second type of analysis is not probabilistic. Let I∗
be the optimal strategy of the ID. This analysis consisted
of finding the thresholds of strategy change, whichdefine
the intervals within the parameter variation range such
that I∗ remains optimal. The thresholds were found by
discretizing the parameter variation range and then by
determining for each parameter value whether the opti-
mal strategy was identical to I∗. This analysis showed
that the three parameters with the reference values clos-
est to the strategy change thresholds were, in the following
order: the two specificities of the EBUS (when the CT scan
is positive and when it is negative) and the specificity of
the TBNA when the CT scan is negative. A small varia-
tion in the value of the specificity of the EBUS was likely
to have an impact because its reference value, 0.995, was
very close to the threshold 0.99.
The third type of analysis, sensitivity of each decision
to each parameter, measured the probability of a change
in the optimal strategy given the second-order uncer-
tainty of each parameter. In the proposed model, the three
parameters that led to the highest probabilities were, in
the following order: (1) the QALE of chemoradiotherapy
survivors when there is metastasis, (2) the QALE of tho-
racotomy survivors when there is metastasis, and (3) the
specificity of the EBUS when the CT scan is negative. The
decisions most affected by variations in these parameters
were, in this order, Dec_EBUS_EUS and Dec_TBNA.
This third metric is inspired in acceptability curves
commonly used in health economic evaluation analyses
[27]. An acceptability curve corresponds to a two-axis
graph, in which the X-axis represents the values in a varia-
tion interval of a parameter, and the Y -axis represents the
probability of a new intervention of being cost-effective
in comparison to a control intervention. The third met-
ric presented here computes instead the probability that
the optimal intervention remains optimal, i.e. is more
cost-effective than any other strategy; then we define the
metric as the complementary of such a probability.
The main conclusion of these analyses is that the result-
ing strategy is robust to the uncertainty of the numerical
parameters because only the specificity of the EBUS when
the CT scan is negative had a significant impact on the
optimal strategy.
Discussion
When the strategies illustrated in Figs. 4 and 5 were pre-
sented to the expert, he agreed with the optimal therapy
calculated by the system. He would follow a slightly dif-
ferent strategy that repeats some tests in specific cases
(restaging), a possibility that was not considered in this
research, but he was not sure whether this strategy is
better than that recommended by MEDIASTINET.
Overall, he was favorably impressed by the “intelligence”
displayed by this model. In particular, he was surprised
that the model recommended TBNA when the CT scan
is positive, which differs from current practice, but he
thinks that this recommendation should be discussed by
the pneumology community because TBNA is a cheap and
useful technique that could avoid an EBUS, an expensive
test, for many patients. One advantage of using an explicit
decision model, publicly available, is that experts can
resolve their differences by introducing different parame-
ters into the model and comparing its recommendations.
Accordingly, experts from a country other than Spain can
introduce different numerical parameters into the model
and thereby obtain the results from the perspective of
their public health system.
The work presented in this paper has several limitations.
First, we have assumed that decisions are totally ordered
in MEDIASTINET. However, the optimal strategy could
be different if other orderings are allowed in the model.
Second, the result of PET after a CT scan can influence
the sensitivity and specificity of EBUS, EUS, TBNA and
mediastinoscopy; if we removed this assumption of inde-
pendence (by drawing arcs from PET to such tests), the
model could recommend PET in certain scenarios of the
strategy with costs. Third, PET can help to detect distant
metastasis, which might lead to a different treatment but
is beyond the scope of the model. Fourth, some authors
are recently combining EBUS and EUS as a single tech-
nique where each test analyzes different regions in the
mediastinum.
The results were evaluated by a single expert; other
experts might disagree with the hypotheses of the model,
the numerical parameters, and the assessment of the
strategies obtained from the ID. However, the advantage
of the recommendations offered in this paper is that they
derive from an evidence-based model, which is publicly
available, together with an open-source software tool for
evaluating it. An expert who disagrees with the conclu-
sions of our study can easily modify themodel and analyze
the resulting recommendation.
We followed a manual approach for building the ID
because the causal relations were very well-known and
we did not have enough clinical data; we incorporated all
the numerical parameters from the literature. If we have
had enough clinical data, other ways of building the model
would have been to learn automatically the structure from
a data set [37], or to use a hybrid approach, such as interac-
tive learning [19], to allow the expert to participate in the
model construction. Sesen et al. [38] offer a good study of
the application of learning algorithms for the construction
of a Bayesian network for lung cancer.
To have an idea of why we chose to build an ID instead
of a decision tree, we can give information here about
the size of the decision tree. The number of leaves in the
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symmetric decision tree can be calculated as the product
of the number of decision scenarios and the number of
ordinary utility nodes. The number of decision scenarios
can be calculated as the cardinal of the Cartesian prod-
uct of the domains of all chance and decision variables
[39], which in the case of the proposed ID it is 186,624.
The number of ordinary utility nodes in the ID is 15.
Thus, the total number of leaves in the symmetric deci-
sion tree is 186, 624 × 15 = 2, 799, 360, which implies
the use of a decision tree is prohibitive in our decision
problem.
Related work
As mentioned in the introduction, Nease and Owens [40]
built an ID for the same problem. The model proposed
here differs from theirs in several respects. First, MEDI-
ASTINET considers the morbidities of the tests and the
cost of tests and therapies, as well as the willingness to
pay, λ. Four new diagnostic tests that were not routinely
used in 1997 [40], have been included in MEDIASTINET,
namely TBNA, PET, EBUS,and EUS. In line with current
practice, MEDIASTINET assumes that a CT scan is always
performed. In MEDIASTINET the result of the CT scan
influences the sensitivity and specificity of subsequent
tests because it gives valuable information about where
to stick the needle when doing other tests. One possible
treatment is not to treat the pateient, although according
to MEDIASTINET it is never the optimal therapy.
As a result of these additions, MEDIASTINET is much
bigger and more complex than the model of Nease and
Owens [40]. In particular, the decision table for treatment
in their model had 72 columns, whereas the number of
columns is 15,552 in MEDIASTINET.
Different authors have applied decision trees3 to the
diagnosis of lung cancer. Different authors [41–44] build
different decision trees for assessing the efficacy of PET
compared to a baseline strategy that only uses a CT scan.
Dietlein et al. [45] performs a similar study, but adding
the possibility of performing a mediastinoscopy in certain
scenarios. In contrast to these proposals, our model con-
tains additional diagnostic tests (TBNA, EBUS and EUS),
and exhaustively studies a much bigger set of strategies.
Closely related to our work, Barosi et al. [46] performed
a cost-effectiveness analysis of testing for occult cancer in
idiopathic deep vein thrombosis. Theirmodel first decides
which cancer to investigate, and, next, for each cancer, it
then has two options: (1) to perform a non-invasive test,
and, if positive, to perform the most invasive test, and (2)
to perform directly the most invasive test. In contrast to
our model, Barosi et al. only considered two tests for each
cancer, as they had to study a set of different cancers. They
only studied two strategies of testing for each cancer, while
our model can decide which tests are more appropriate in
each scenario, and thus, explore a bigger set of strategies.
Other artificial intelligence approaches have been
applied to the diagnosis of lung cancer. Wu et al. [47]
selected and grouped some tumor biomarkers through
multiple logistic regression, and then used them as inputs
for an artificial neural network. Wnuk et al. [48] used
an artificial neural network for predicting mediastinal
lymph node metastases in NSCLC. Nie et al. [49] stud-
ied the diagnosis and prediction of lung cancer of three
models with tumor markers based on different classifica-
tion approaches: logistic regression analysis, decision tree
induction and artificial neural networks. Despite the high
diagnostic capabilities of these approaches, we think it
would still be necessary to integrate them into a frame-
work that can automatically calculate the optimal deci-
sions based on utilities such as costs, life expectancy and
willingness-to-pay, similar to what, for example, an ID can
do.
Conclusions
There is a vigorous debate among medical special-
ists about the optimal sequence of tests for the medi-
astinal staging of NSCLC [3, 4]. For this reason, we
have built MEDIASTINET, a probabilistic model that
combines objective data and subjective estimates. It is
publicly available and can be evaluated with Open-
Markov. Experts can populate this model with differ-
ent parameters and analyze whether their differences
of opinion are due to discrepancies in the condi-
tional probabilities they are using or to different struc-
tural hypotheses. Accordingly, the model proposed here
might be a useful decision analysis tool for reaching a
consensus.
Moreover, the explicit inclusion of willingness to pay in
the proposed model makes it possible to adapt it to each
decision-maker; for example, in rich countries λ is much
higher than in poor regions.
From the perspective of IDs, one contribution of this
work is the algorithm for synthesizing huge decision tables
into very compact strategy trees, a facility that is not avail-
able in other software packages for IDs other than in
OpenMarkov.
The quantitative uncertainty in our model has been
represented by assigning to each independent parame-
ter the most appropriate distribution, as is usual in the
literature. We have applied three metrics for sensitivity
analysis: the EVPI of each parameter, the strategy change
thresholds, and the sensitivity of each decision to each
parameter. These three methods have proven that the
proposed model is robust to numerical parameter uncer-
tainty, except the specificity of the EBUS when the CT
scan is negative.
As a possibility for future work, we can refine the ID
by making the result of PET influence the sensitivity and
specificity of subsequent tests. This task would require
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an in-depth review of the literature due to the expo-
nential growth of the number of parameters required in
probability tables.
We may allow partial orderings of the decisions by
building a decision analysis network (DAN) [50] instead
of an ID. However, the main difficulty would be collecting
clinical data to elicit these parameters.
The expert would also like to include in the model
the possibility of repeating some diagnostic tests to
some patients with N2-positive, previously treated with
chemotherapy, to reevaluate them as candidates for
surgery, in a process known as restaging. For that purpose,
various dynamic representations could be considered,
such as partially observable Markov decision processes
[51], and dynamic limited memory influence diagrams
[52], but again the problem would be the lack of clinical
data to estimate the numerical parameters.
Our model assumes that a CT scan is performed on
every patient. However, it would be interesting to select a
different starting point for the test sequence.
We could constitute a panel of experts to know their
opinion about the results of the model. As we men-
tion above, debugging MEDIASTINET with OpenMarkov
should help to reach a consensus when experts disagree.
An interesting future work would be to obtain access to
a large data set and then to consider learning automati-
cally the model [37], in a similar way to how Sesen et al.
[38] built a Bayesian network for lung cancer.
Another line for future research would be to develop
new explanation capabilities, which are crucial to facili-
tate construction of probabilistic decision models and to
communicate with experts [20, 21].
Data availability
The model is publicly available at http://www.
probmodelxml.org/networks/id/ID-mediastinet.pgmx.
It can be evaluated with OpenMarkov, an open-source
software tool that can be downloaded from www.
openmarkov.org.
Endnotes
1Ideally, we would also want to minimize other quanti-
tative factors, such as the emotional costs involved for the
patient and her/his family, as an ID model for neonatal
jaundice did [53]. However, including more criteria apart
from monetary and health functions, would require an
additional study of the additivity properties in the util-
ity function so that it would still be possible to use the
framework of IDs with SVNs.
2Since all costs considered in the model are economic,
in the rest of the paper we will just use the term cost to
refer to them.
3When mentioning “decision trees” we are referring to
the tree-like representation of decision problems under
uncertainty [54] used in decision analysis, in contrast
to induction decision tree approaches used in automatic
learning and classification [55].
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